Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Samfara completa la adquisición de Chr. Olesen Synthesis, fabricante danés de APIs sujetos a control

      • USA - English
      • USA - Français
      • USA - Deutsch
      • USA - English
      Samfara

      News provided by

      Samfara LLP

      Oct 02, 2026, 02:00 ET

      Share this article

      Share this article


      Esta adquisición constituye la primera inversión de Samfara y cuenta con el respaldo de un consorcio de inversores institucionales y family offices de Europa y Norteamérica.

      LONDRES, 2 de octubre de 2026 /PRNewswire/ -- Samfara, una firma europea de inversión en ciencias de la vida, anunció hoy que ha completado la adquisición de Chr. Olesen Synthesis de Chr. Olesen y a fondos gestionados por Signet Healthcare Partners. El consejero delegado, Thomas Moestrup, participa en la inversión junto a Samfara. No se divulgaron los términos financieros de la operación.

      Con sede cerca de Copenhague, Chr. Olesen Synthesis desarrolla y fabrica principios activos farmacéuticos (API) e intermedios avanzados, especializándose en sustancias controladas, en particular las utilizadas para tratar el trastorno por consumo de opioides (buprenorfina) y el TDAH (lisdexanfetamina). Su planta, certificada según las normas cGMP, opera a nivel comercial desde 2015 y abastece a empresas farmacéuticas de Europa, Norteamérica y Oriente Medio. La compañía combina experiencia técnica y una gran flexibilidad para atender a sus clientes del sector farmacéutico en los distintos mercados en los que opera.

      Con el respaldo de Samfara, Chr. Olesen Synthesis seguirá desarrollando sus capacidades, consolidando su cartera de clientes y productos, y expandiéndose hacia nuevos mercados. Jean-François Hilaire, exconsejero delegado de Unither y exvicepresidente ejecutivo de Recipharm, quien asesoró a Samfara en la operación de adquisición, se incorporará al consejo de administración de Chr. Olesen Synthesis en calidad de presidente.

      Helena Malchione y James Cocker, socios de Samfara, declararon:

      "Chr. Olesen Synthesis ejemplifica nuestra estrategia de identificar empresas exitosas en nichos complejos y respaldarlas con capital y apoyo estratégico. La compañía goza de una posición sólida y una excelente reputación en un segmento exigente del mercado farmacéutico; esperamos colaborar con Thomas y su equipo a medida que crecen con sus clientes actuales y se expanden hacia nuevos mercados, tanto de forma orgánica como mediante adquisiciones".

      Thomas Moestrup, consejero delegado de Chr. Olesen Synthesis, dijo: 

      "Este es un paso adelante muy prometedor para Chr. Olesen Synthesis. Con Samfara como nuevo propietario, contamos con un socio que comparte nuestras ambiciones y respaldará el desarrollo continuo del negocio. Esperamos seguir fortaleciendo nuestras relaciones con los clientes, expandir la actividad y aprovechar las oportunidades que tenemos por delante".

      Mads C. Olesen, consejero delegado y propietario de Chr. Olesen, comentó: 

      "En 2011, Chr. Olesen adquirió Chr. Olesen Synthesis y, junto con Signet Healthcare, la ha convertido en un actor relevante en el ámbito de los principios activos farmacéuticos (API) de sustancias controladas. Es el momento adecuado para que nuevos propietarios impulsen el negocio, y estamos convencidos de haber confiado la empresa al propietario idóneo. Deseamos lo mejor a Samfara y al equipo directivo de la compañía".

      ASESORES

      Samfara contó con el asesoramiento de Addleshaw Goddard (legal, Reino Unido), Connaught (captación de capital), infotransactions (debida diligencia financiera y fiscal), Lockton (seguro W&I), Nivaro Law (legal, Dinamarca) y RSM (estructuración fiscal).

      Chr. Olesen y Signet Healthcare Partners contaron con el asesoramiento de LEK (comercial), Moalem Weitemeyer (legal), Nielsen Nørager (legal), PwC (financiero y fiscal), Sheppard, Mullin, Richter & Hampton (legal) y Stifel (fusiones y adquisiciones).

      ACERCA DE SAMFARA
      Samfara es una firma de capital privado con sede en Londres centrada en compras mayoritarias de empresas europeas de ciencias de la vida en el mercado medio-bajo. La firma realiza inversiones basadas en tesis en negocios internacionales complejos cuyo rendimiento puede acelerarse y transformarse mediante la propiedad activa. Samfara tiene como objetivo ofrecer rentabilidades atractivas para los inversores y al mismo tiempo apoyar a las empresas europeas de ciencias de la vida, los empleos que crean y los pacientes a los que benefician.

      www.samfara.com

      Samfara LLP es un representante designado de Suntera Advisers (UK) Limited, entidad autorizada y regulada por la Financial Conduct Authority.

      ACERCA DE CHR. OLESEN SYNTHESIS
      Chr. Olesen Synthesis es una empresa danesa dedicada al desarrollo y la fabricación de principios activos farmacéuticos (API) e intermedios avanzados, especializada en sustancias controladas. Desde su planta con certificación cGMP en Hvidovre, cerca de Copenhague, abastece a compañías farmacéuticas de Europa, Norteamérica y Oriente Medio, y ofrece servicios de desarrollo y fabricación por contrato para nuevos API.

      www.cosynthesis.dk

      ACERCA DE CHR. OLESEN
      Chr. Olesen, fundada en 1885, es una empresa familiar de distribución global especializada en ingredientes nutracéuticos para los sectores de alimentación animal, alimentación humana, farmacéutico e industrial.

      www.chr-olesen.dk

      ACERCA DE SIGNET HEALTHCARE PARTNERS
      Signet Healthcare Partners es una firma de capital de crecimiento especializada en el sector sanitario que invierte en empresas de tecnología médica y del sector farmacéutico (servicios farmacéuticos y terapias) que se encuentran en fase comercial. Fundada en 1998 y con sede en Nueva York, Signet ha invertido en más de 60 empresas, apoyando a los emprendedores con capital, orientación estratégica y una amplia red de contactos en el sector.

      www.signethealthcarepartners.com

      CONTACTOS

      Samfara
      Helena Malchione, socio
      [email protected]

      James Cocker, socio
      [email protected]

      Chr. Olesen Synthesis
      Thomas Moestrup, consejero delegado
      [email protected]

      Modal title

      Also from this source

      Samfara finalise l'acquisition de Chr. Olesen Synthesis, fabricant danois de principes actifs pharmaceutiques (API) soumis à un contrôle réglementaire

      Samfara finalise l'acquisition de Chr. Olesen Synthesis, fabricant danois de principes actifs pharmaceutiques (API) soumis à un contrôle réglementaire

      Samfara, une société européenne d'investissement spécialisée dans les sciences de la vie, a annoncé aujourd'hui avoir finalisé l'acquisition de Chr....

      Samfara completes acquisition of Chr. Olesen Synthesis, Danish manufacturer of controlled-substance APIs

      Samfara completes acquisition of Chr. Olesen Synthesis, Danish manufacturer of controlled-substance APIs

      Samfara, a European life sciences investment firm, today announced that it has completed the acquisition of Chr. Olesen Synthesis from Chr. Olesen...

      More Releases From This Source

      Explore

      Banking & Financial Services

      Banking & Financial Services

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.